Lexicon Pharmaceuticals (LXRX, Financial) has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of LX9851, a groundbreaking oral treatment for obesity and related metabolic disorders. This deal could potentially bring Lexicon up to $1 billion, including $75 million in upfront and near-term milestone payments. LX9851, targeting the ACSL5 enzyme, has shown promising preclinical results in managing weight and improving metabolic conditions when combined with semaglutide.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Lexicon Pharmaceuticals Inc (LXRX, Financial) is $2.60 with a high estimate of $6.00 and a low estimate of $0.80. The average target implies an upside of 313.42% from the current price of $0.63. More detailed estimate data can be found on the Lexicon Pharmaceuticals Inc (LXRX) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Lexicon Pharmaceuticals Inc's (LXRX, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
